Trial Profile

A first-in-human trial of ZI-MA4-1

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Oct 2025 New trial record
20 Aug 2025 Accoridng to a Zelluna Immunotherapy media release, following positive FDA pre-IND feedback (Q2 2024), submitted a scientific advice briefing package to the UK MHRA in July 2025 for ZI-MA4-1.
20 Aug 2025 According to a Zelluna Immunotherapy media release, the company remains, on track for IND/CTA submission in the second half of 2025 and initiation of its first-in-human trial in the first half of 2026, supported by leading clinical experts and sites, with a refined trial design and preparations underway for operational readiness ahead of submission.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com